PDCD1 and kidney cancer: Immune checkpoint blockade therapies such as those targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte–associated antigen 4 are effective for the treatment of skin, lung, mesothelioma, bladder and kidney cancers.37